A 5 yr old intact female cocker spaniel dog weighing 7.8 kg was referred with anorexia, vomiting, and depression. At referral, the dog was diagnosed initially with typical hypoadrenocorticism, and 2 d later, concurrent primary hypothyroidism was detected. Hormonal replacement therapies, including fludrocortisone, prednisolone, and levothyroxine, were initiated, but a few days later the dog became abruptly tachypneic, and thoracic radiographs indicated the development of pulmonary edema. Echocardiography showed that there were abnormalities indicating impaired left ventricular function, although the heart valves were normal. Following treatment with pimobendan and furosemide, the pulmonary edema resolved. The dog had no recurrence of the clinical signs after 10 mo of follow-up, despite being off all cardiac medications; consequently, the cardiac failure was transient or reversible in this dog. The case report describes the stepwise diagnosis and successful treatment of cardiogenic pulmonary edema after initiation of hormonal replacement therapy for concurrent hypoadrenocorticism and hypothyroidism in a dog. (J Am Anim Hosp
Introduction
Polyendocrinopathies have been reported in only single case reports or small case series in veterinary medicine, so there is a lack of information about successful treatments for combined hypoadrenocorticism and hypothyroidism in dogs. [1] [2] [3] Endocrine hormone deficiencies have been associated with cardiac dysfunction and heart failure. Among hormone deficiencies causing cardiac abnormalities in humans, the most consistently reported is hypothyroidism. 4, 5 In dogs, there has been only one report of dilated cardiomyopathy and congestive heart failure caused by hypothyroidism. 6 The link between adrenal insufficiency and heart failure has been described in humans. [7] [8] [9] [10] However, to the best of the authors' knowledge, it has not been reported previously in dogs. The case reported herein describes the diagnosis and treatment of cardiogenic pulmonary edema after hormonal replacement therapy for concurrent hypoadrenocorticism and hypothyroidism in a cocker spaniel dog. At referral (day 0), the dog appeared slightly lethargic. Cardiac auscultation detected an irregular rhythm bradycardia with a heart rate of 60 beats per minute but no heart murmur. The mucous membranes were dry and tacky, and a skin tent was visible. 
Case Report
Na, sodium; K, potassium; BUN, blood urea nitrogen; NT-proBNP, amino terminal probrain natriuretic peptide; cTNI, cardiac troponin I; RI, reference interval a The day when bradycardia with junctional rhythm was detected in electrocardiographs. See Figure 2 for details. b ND, not done.
and had a normal appetite, and her heart rate was within the normal reference range ( Figure 2C ). The following day, the administration of IV fluid was discontinued.
On day 6 of hospitalization, however, the dog became acutely tachypneic. Thoracic radiographs revealed a diffuse increased alveolar and interstitial pattern that was most severe in the hilar region. This was consistent with pulmonary edema ( Figure 1B ). promptly. On day 7, the thoracic radiographs detected reduced pulmonary edema, and the dog's tachypnea was improved. On day 9, she was discharged.
On day 11, the owner reported that the dog remained lethargic and had no appetite, but the thoracic radiographs showed no 
Discussion
In this case, a dog was diagnosed as suffering from a polyendocrinopathy, which comprised hypoadrenocorticism and hypothyroidism, and, after the initiation of hormonal replacement therapy, developed suspected cardiogenic pulmonary edema.
Although the exact cause of the pulmonary edema was difficult to determine, several possibilities were considered, such as the effects of the two endocrine diseases (hypoadrenocorticism and hypothyroidism) and the effect of hormonal replacement therapy on cardiac function.
FIGURE 2 Electrocardiographs (ECGs) recorded from a cocker spaniel dog with hypoadrenocorticism and hypothyroidism. (A) At initial
presentation, the lead II ECG detected an intermittent loss of P wave, a decreased QRS amplitude, and peaking of the T waves with a ventricular rate of 78 beats/min, which were consistent with hyperkalemia, while the serum potassium concentration was 9.2 mmol/L at this time. (B) Lead II ECG recording after correction of hyperkalemia. The ECG detected a junctional rhythm for first, third, and fifth complex with small QRS complexes, followed by peaking of the T waves and a heart rate of 54 beats/min. (C) Lead II ECG recording after the administration of levothyroxine. The ECG detected a heart rate of 120 beats/min.
First of all, we considered the possibility that fludrocortisone administration contributed to volume overload. Fludrocortisone acetate, a synthetic steroid with potent mineralocorticoid action, has been reported to have a number of side effects, including congestive heart failure, hypernatremia, hypokalemia, and hyperglycemia. 13 In humans, fludrocortisone acetate administration at an optimal dose resulted in congestive heart failure in an infant diagnosed with hypoadrenocorticism who had developed systemic hypertension as a result of the treatment. 14 In two other cases of fludrocortisone therapy for hypoadrenocorticism, a pediatric patient experienced peripheral edema and cardiac failure, despite the fact that the dose employed was within the doses specified by pediatric endocrinology guidelines and an adult patient experienced pulmonary edema 2 wk after the administration of an optimal dose of fludrocortisone. 8, 9 The authors speculated that renal adaptation to chronic salt and water deprivation may have played a role in the sensitivity of these patients to fludrocortisone replacement therapy. 8, 9 That is, once mineralocorticoid replacement treatment was begun, the previous adaptive mechanism may have resulted in sodium and water retention, leading to congestive heart failure. 8, 9 To the authors' knowledge, there have been no previous reports of an association between congestive heart failure and fludrocortisone therapy for hypoadrenocorticism in dogs.
In the present case, there was no suggestion of abnormal Therefore, we assumed that the congestive heart failure was caused by poor left ventricular contractility, and although we could not confirm decisively that fludrocortisone therapy was the cause of congestive heart failure, it could at least have been a contributory factor for the congestive heart failure.
Second, there was the possibility that myocardial dysfunction was caused by glucocorticoid insufficiency. Glucocorticoids have been shown to be important for the maintenance of membrane calcium transport in the cardiac sarcoplasmic reticulum in rats, which may affect myocardial contractility. 15 It has also been demonstrated that rats may develop impaired myocardial excitation-contraction coupling because of reduced phosphorylase activity following adrenalectomy. 16 The dog reported here was diagnosed with hypoadrenocorticism immediately at presentation, but presumably also had an unrecognized preceding chronic adrenal insufficiency. The absence of a variety of glucocorticoid effects required for the maintenance of the adrenergic tone in the vascular bed could have contributed to the low systemic vascular resistance. Therefore, afterload at initial presentation may have been depressed and could have masked the poor contractile state.
In this respect, there was a possibility that the depressed contractile state of the left ventricle only became obvious after volume resuscitation and the increase in afterload.
Last, the dog had thyroid hormone insufficiency. It has been
shown that a rapid return to a euthyroid state can sometimes result in myocardial ischemia. 5 Furthermore, the higher metabolic rate associated with a return to a euthyroid state can increase myocardial workload and contribute to the likelihood of heart failure. 17, 18 In addition, because thyroid hormone supplementation can increase myocardial oxygen demand, thyroid hormone supplementation in hypothyroid dogs with underlying cardiac disease may cause cardiac decompensation. 19 Therefore, we speculated that thyroid hormone therapy was decisive for the development of congestive heart failure in our case. The current recommendations for hypothyroid dogs with cardiac disorders include an initial dose of thyroid hormone replacement, which should be 25% to 50% of the usual starting dose, followed by a gradual increase to avoid a sudden change in metabolic demand. 19 It has also been suggested that the initial dose of levothyroxine should be decreased to 50% of the usual dose in hypothyroid dogs with concurrent hypoadrenocorticism because the increased basal metabolic rate may exacerbate electrolyte disturbance. 19, 20 Although we initially used a dose of levothyroxine that was half the currently recommended guidelines for hypothyroid dogs with concurrent hypoadrenocorticism, the dog nonetheless developed congestive heart failure. Therefore, we advocate the use of a conservative dose of levothyroxine during initial therapy (i.e., 25% of the recommended dose).
Meanwhile, the myocardium is known to be especially sensitive to the effects of thyroid hormone. [4] [5] [6] 21 Therefore, decreased concentrations of circulating thyroid hormone are associated with many clinically recognizable effects, including a lower heart rate, a lower inotropic state of the myocardium, and a dilated intraventicular lumen. [4] [5] [6] 21 Although it is still controversial whether hypothyroidism truly causes significant clinical cardiac disease, congestive heart failure associated with reduced myocardial contractility has been documented in two hypothyroid dogs and was partially or fully reversed by thyroid hormone therapy. 6 In the present case, however, the increase in left ventricular FS following levothyroxine replacement therapy was inadequate. In addition, an infiltration of the myocardium with mucopolysaccharides in hypothyroid dogs has been reported to result in coronary arterial atherosclerosis, which may result in prolonged impairment of cardiac function. 22 It has been also suggested that a more prolonged period of hypothyroidism may result in permanent, irreversible ultrastructural changes in the myocardium. 6 In our case, the dose of prednisolone was increased from 0.1 mg/kg (q 12 h) to 0.5 mg/kg (q 12h), with the increase in the dose of levothyroxine and the switching from fludrocortisones to DOCP. The increase in the prednisolone dose was because cortisol clearance could be affected by thyroid function. The increased metabolic rate accompanying thyroxine replacement in the hypothyroid patients increases the cortisol requirements. 23 In humans, it has been suggested that patients with adrenal insufficiency and untreated hyperthyroidism should receive two or three times their usual glucocorticoid replacement dose to compensate for the increased cortisol clearance owing to the hyperthyroid state. 24, 25 Moreover, it is recommended that thyroxine replacement in patients with hypothyroidism should start to prevent adrenal crises after the adrenal insufficiency has been excluded or treated. 25 Therefore, in the present case, it was possible that the levothyroxine supplementation to overcome chronic hypothyroid state might have resulted in the increased cortisol clearance. However, there is a lack of evidence on the correlation between the cortisol clearance and thyroxine replacement in dogs.
In conclusion, the pathophysiology of congestive heart failure in this dog might have been multifactorial, although the dog's pulmonary edema appeared to be a consequence of the effect of hormonal replacement therapy on cardiac function. There was a possibility that the dog had underlying heart disease that was subclinical and exacerbated by having two endocrine disorders. It is also possible that the patient developed congestive heart failure secondary to all of our therapies, not just the hormonal therapy, because the dog initially received fairly aggressive fluid therapy. 
